Aikido Pharma Inc.

Dominari Holdings, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022.

AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK , Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses.

AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

NEW YORK , Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on October 5, 2022, the Company purchased 10,500 shares of common stock at $7.0679 per share.

AIkido Share Repurchase Continues

NEW YORK , Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share.

AIkido Purchases More Shares

NEW YORK , Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on October 3, 2022, the Company purchased 45,000 shares of common stock at $6.98 per share.

Share Repurchase Program Continues

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on September 30, 2022, the Company purchased 41,096 shares of common stock at $ 7.1034 per share.

AIkido Pharma Continues Share Repurchase Program

NEW YORK , Sept. 30, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

AIkido Pharma Provides Update on Share Repurchase Program

Acquisition Will Accelerate Growth Strategy NEW YORK , Sept. 9, 2022 /PRNewswire/ -- Dominari Financial, Inc., the financial services subsidiary of AIkido Pharma Inc., (NASDAQ: AIKI) has entered into an exclusive agreement for the acquisition of a broker-dealer firm.

Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-Dealer

NEW YORK , Aug. 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today confirms that on August 9, 2022, the Company received an unsolicited offer from Mr. Shalom Auerbach to acquire all of the Company's outstanding common stock for $8.00 per share in cash.

AIkido Pharma Confirms Receipt of Unsolicited Offer

Morgan Stanley Executive Joins Dominari Financial, Inc. on July 22, 2022 NEW YORK , July 21, 2022 /PRNewswire/ -- Anthony Hayes, CEO of AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company"), announced the hiring of Carlos Aldavero as President of Dominari Financial, the recently formed financial services subsidiary of AIkido. Mr. Aldavero joins Dominari from Morgan Stanley where he was Associate Complex Manager overseeing one of the largest and most profitable business units at the venerable Wall St. firm.

AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial Services Subsidiary

NEW YORK , June 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on June 23, 2022, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ's requirements when the closing bid price for the Company's common stock was at or above $1.00 for 10 consecutive business days and the matter is now closed.

AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

Long-Range Strategy Seeks Diversification into Three Key Industries NEW YORK , June 24, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") announced the formation of a wholly owned subsidiary with the purpose of making strategic investments and acquisitions across the fintech and financial services industries. The new subsidiary is expected to be the centerpiece of a long-range plan to diversify AIkido's business beyond biotechnology, in order to reduce volatility and mitigate risk while increasing revenue and enhancing shareholder value.

AIkido Inc. Announces the Formation of a New Financial Services Subsidiary

New Director Supports NASDAQ Rule on Diversity NEW YORK , June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company.

AIkido Pharma Inc. Appoints New Director, Soo Yu

AIkido Pharma (AIKI) stock is skyrocketing on Tuesday but it's not due to any positive news from the biotechnology company. The post Why Is AIkido Pharma (AIKI) Stock Up 1,400%?

Why Is AIkido Pharma (AIKI) Stock Up 1,400%?

A 1 for 17 reverse stock split of AIkido Pharma, Inc. (NASDAQ: AIKI) has gone into effect. These are the details.

Aikido Pharma (AIKI) Stock Price: 1-For-17 Reverse Split Goes Into Effect

Shares of AIkido Pharma Inc. slumped 11.3% to pace all the premarket decliners Tuesday, after the biotechnology company's 1-for-17 reverse stock split took effect.

AIkido Pharma stock falls again after reverse stock split takes effect

NEW YORK , June 3, 2022 /PRNewswire/ -- AIkido Pharma, Inc. (NASDAQ:AIKI), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 17 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m.

AIkido Announces Reverse Stock Split

NEW YORK, May 19, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the Company's commitment to complying with the NASDAQ listing requirements on board diversity by August 1, 2022. Anthony Hayes, CEO of AIkido stated, "Board diversity and inclusion is an important issue.

AIkido Pharma Announces Company Commitment to Board Diversity

Data and AI Company and a Pioneer of the Cutting-Edge Database Architecture NEW YORK , May 12, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company, through a fund that owns the stock, has acquired an economic interest in privately held Databricks Inc.  (https://databricks.com/company/about-us).  The acquisition has been funded and closed, and the asset is on the Company's balance sheet.

AIkido Pharma Secures Interest in Databricks Inc.

Company's Flagship Product, The Slinger Bag, Top Rated Among 2022 Tennis Products NEW YORK , May 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today reported that, on March 30, 2022, Slinger Bag Inc. ("Slinger Bag") filed a Form S-1/A with the Securities and Exchange Commission ("SEC") requesting that the company's shares of common stock be publicly listed on the Nasdaq Capital Market under the symbol "CNXA."   AIkido previously announced that it entered into an August 6, 2021, securities purchase agreement with Slinger Bag, which is the maker of The Slinger Bag, an advanced tennis ball shooter with a wheeled-bag design.

AIkido Reports Slinger Bag Inc.'s Filing for Nasdaq Public Listing

Discord Reportedly Interviewing Investment Bankers About Going Public This Year NEW YORK , May 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has secured an early equity interest in privately-held Discord, Inc. (https://discord.com/), a social communications platform provider that is particularly popular with gamers. Bloomberg Technology reported on March 14, 2022, that Discord "is interviewing bankers about going public as soon as this year.

AIkido Pharma Announces Strategic Investment in Social Communications Platform Provider Discord, Inc.

Analysis Firm Agrees that Reverse Split Is in the Best Interest of the Company NEW YORK , April 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today reported that, on April 20, 2022, the independent Proxy Paper analysis firm Glass Lewis issued a report ("GL Report") providing an analysis of the proposals contained in the Company's "Proxy Statement for 2022 Annual Meeting of Stockholders May 20, 2022," which was filed with the Securities and Exchange Commission on April 12, 2022.  With respect to Proposal (4) in the Proxy Statement to effect a reverse split of the Company's common stock, the GL Report recommends "FOR" the proposal.

Glass Lewis Proxy Paper Report Recommends "FOR" AIkido Pharma Inc. Proposed Reverse Stock Split

Masterclass Provides Members Access to Pre-Recorded Lectures by Top Experts NEW YORK , April 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has secured an early equity interest in privately-held Yanka Industries, Inc., doing business as MasterClass (https://www.masterclass.com/). MasterClass is self-described as the "streaming platform where the world's best come together so anyone, anywhere, can access and be inspired by their knowledge and stories.

AIkido Pharma Announces Strategic Investment in MasterClass

NEW YORK, March 11, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Collaboration Agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient's own "killer" T-cells. The Company and Cedars-Sinai will share costs, expenses and management of the drug co-development and will leverage the talent of Cedars-Sinai Technology Ventures and the lead scientists who originated the novel treatment.

Cedars-Sinai Medical Center and AIkido Pharma Inc. to Codevelop Novel Immuno-Oncology Cancer Treatment

NEW YORK, March 8, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has entered into a Master Collaboration Agreement (MCA) with Cedars-Sinai Medical Center. The purpose of the MCA is to collaborate in the funding and commercialization of discoveries and technologies developed at Cedars-Sinai.

News for Aikido Pharma Inc. Stock (AIKI)